Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. (KYMR) priced its initial public offering on Aug 21, 2020 at $20.00 per share, above its $16.00–$18.00 range, raising $173.7M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $862.8M. Morgan Stanley was lead-left underwriter, joined by BofA Securities, TD Cowen and Guggenheim. Goodwin Procter advised the company and WilmerHale advised the underwriters.

Kymera Therapeutics, Inc. is a biopharmaceutical company discovering small molecule therapeutics that selectively degrade disease-causing proteins using the body's natural protein degradation system. Its targeted protein degradation platform is called Pegasus.

Status

IPO

Ticker

KYMR

Exchange

Nasdaq Global Market

Priced

Aug 21, 2020

IPO price

$20.00

Price range

$16.00–$18.00

Raised

$173.7M

Market cap at IPO price

$862.8M

First filed

Jul 31, 2020

Underwriters

Morgan Stanley, BofA Securities, TD Cowen and Guggenheim

Company counsel

Goodwin Procter

Underwriters' counsel

WilmerHale

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.